Based on targeted NGS panel results, metastatic gastric cancer patients with gene amplifications will receive either anti-EGFR antibody (GC-1118) in combination with weekly paclitaxel as a second-line therapy.
Participants will receive each treatment if the gastric cancer tissue sample reveals either EGFR gene amplification or strong (3+ or 2+) EGFR immunostaining
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
19
Intravenous GC-1118 in combination with weekly paclitaxel for EGFR-amplified cancer cancers as a second-line therapy
National Cancer Center
Goyang-si, Gyeonggi-do, South Korea
RECRUITINGResponse rate
Response rate will be assessed using CT/MRI according to RECIST v1.1.
Time frame: Response rate will be assessed at 8 weeks.
Progression-free survival
Time from date of enrollment until the date of first documented progression or the date of death from any cause, whichever came first, will be assessed.
Time frame: From date of enrollment until the date of first documented progression or the date of death from any cause, whichever came first, will be assessed up to 1 year.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.